AU6091496A - Antibodies to fas antigen capable of inhibiting apoptosis - Google Patents

Antibodies to fas antigen capable of inhibiting apoptosis

Info

Publication number
AU6091496A
AU6091496A AU60914/96A AU6091496A AU6091496A AU 6091496 A AU6091496 A AU 6091496A AU 60914/96 A AU60914/96 A AU 60914/96A AU 6091496 A AU6091496 A AU 6091496A AU 6091496 A AU6091496 A AU 6091496A
Authority
AU
Australia
Prior art keywords
antibodies
fas antigen
inhibiting apoptosis
antigen capable
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60914/96A
Inventor
Thomas Gesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU6091496A publication Critical patent/AU6091496A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU60914/96A 1995-06-07 1996-06-05 Antibodies to fas antigen capable of inhibiting apoptosis Abandoned AU6091496A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48346195A 1995-06-07 1995-06-07
PCT/US1996/009153 WO1996040041A2 (en) 1995-06-07 1996-06-05 Antibodies to fas antigen capable of inhibiting apoptosis
US483461 2000-01-13

Publications (1)

Publication Number Publication Date
AU6091496A true AU6091496A (en) 1996-12-30

Family

ID=23920122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60914/96A Abandoned AU6091496A (en) 1995-06-07 1996-06-05 Antibodies to fas antigen capable of inhibiting apoptosis

Country Status (2)

Country Link
AU (1) AU6091496A (en)
WO (1) WO1996040041A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO971448L (en) * 1996-04-01 1997-10-02 Sankyo Co Recombinant anti-Fas antibodies and DNA for these
WO1998018487A1 (en) * 1996-10-31 1998-05-07 Mochida Pharmaceutical Co., Ltd. Prophylactic/remedial agent
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
WO2003022299A1 (en) * 2001-08-01 2003-03-20 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
KR20110128923A (en) * 2009-03-12 2011-11-30 이메드 아베 Human antibodies against human fas and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
AU705114B2 (en) * 1993-10-14 1999-05-13 Immunex Corporation Fas antagonists and uses thereof
DE4447484C2 (en) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Apoptosis inhibitor

Also Published As

Publication number Publication date
WO1996040041A2 (en) 1996-12-19
WO1996040041A3 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
AU1273697A (en) Therapeutic uses of humanized antibodies against alpha-4 integrin
AU7264296A (en) Technique of incorporating floating point information into processor instructions
AU5674696A (en) Compounds that bind to p185 and methods of using the same
AU1704099A (en) Monoclonal human natural antibodies
AU6034296A (en) Tricyclic inhibitors of protein farnesyltransferase
AU5744696A (en) In situ immunodetection of antigens
AU4094297A (en) Monoclonal antibodies specific to cooked meats
AU4618193A (en) Humanized antibodies
IL179619A0 (en) Antibodies to modulators of the function of the tnf receptors
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
AU6692996A (en) Inhibitors of apoptosis
AU5921096A (en) Iodine complex of alkyl polyglycosides
IL116924A (en) Preparation of n-aryl - and n-hetarylhydroxylamines
AU2399395A (en) Improved modeling of multi-disciplinary signals
AU6155896A (en) Humanized antibodies to e-selectin
AU6091496A (en) Antibodies to fas antigen capable of inhibiting apoptosis
AU3696289A (en) Anti-fc assay for detection of antibodies
AU5937598A (en) Humanized anti-human Fas antibody
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU7113696A (en) Detection and quantitation of 8-oh-adenine using monoclonal antibodies
AU2365795A (en) Multiple administrations of anti-tnf antibody
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
AU6516996A (en) Preparation of drinks
AU5629096A (en) Synthesis of difluoromethane
AU6560196A (en) Cytohesin-PH peptides that affect the ability of integrins to adhere